PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia
Abstract
Authors
M. Hoyle T. Pavey O. Ciani L. Crathorne T. Jones-Hughes C. Cooper L. Osipenko M. Venkatachalam C. Rudin O. Ukoumunne R. Garside R. Anderson